283 related articles for article (PubMed ID: 24884806)
1. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer.
Micali S; Bulotta S; Puppin C; Territo A; Navarra M; Bianchi G; Damante G; Filetti S; Russo D
BMC Cancer; 2014 Apr; 14():303. PubMed ID: 24884806
[TBL] [Abstract][Full Text] [Related]
2. [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].
Spitzweg C
Internist (Berl); 2003 Apr; 44(4):396-402, 404-8, 410-1. PubMed ID: 12914397
[TBL] [Abstract][Full Text] [Related]
3. The sodium iodide symporter: its pathophysiological and therapeutic implications.
Spitzweg C; Morris JC
Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
[TBL] [Abstract][Full Text] [Related]
4. [The practical relevance of the sodium iodide symporter].
Spitzweg C
Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():25-32. PubMed ID: 15255310
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
6. The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues.
Riesco-Eizaguirre G; Santisteban P; De la Vieja A
Endocr Relat Cancer; 2021 Sep; 28(10):T141-T165. PubMed ID: 34387194
[TBL] [Abstract][Full Text] [Related]
7. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond.
Dohán O; Carrasco N
Mol Cell Endocrinol; 2003 Dec; 213(1):59-70. PubMed ID: 15062574
[TBL] [Abstract][Full Text] [Related]
8. Sodium iodide symporter-based strategies for diagnosis and treatment of thyroidal and nonthyroidal malignancies.
Heufelder AE; Morgenthaler N; Schipper ML; Joba W
Thyroid; 2001 Sep; 11(9):839-47. PubMed ID: 11575853
[TBL] [Abstract][Full Text] [Related]
9. A perspective view of sodium iodide symporter research and its clinical implications.
Riesco-Eizaguirre G; Santisteban P
Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
[TBL] [Abstract][Full Text] [Related]
10. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.
Ravera S; Reyna-Neyra A; Ferrandino G; Amzel LM; Carrasco N
Annu Rev Physiol; 2017 Feb; 79():261-289. PubMed ID: 28192058
[TBL] [Abstract][Full Text] [Related]
11. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
12. Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma.
Gaertner FC; Rohde F; Mueller J; Blechert B; Janssen KP; Essler M
Int J Cancer; 2009 Dec; 125(12):2783-91. PubMed ID: 19569179
[TBL] [Abstract][Full Text] [Related]
13. Sodium iodide symporter in health and disease.
Shen DH; Kloos RT; Mazzaferri EL; Jhian SM
Thyroid; 2001 May; 11(5):415-25. PubMed ID: 11396700
[TBL] [Abstract][Full Text] [Related]
14. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
15. Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.
Fletcher A; Read ML; Thornton CEM; Larner DP; Poole VL; Brookes K; Nieto HR; Alshahrani M; Thompson RJ; Lavery GG; Landa I; Fagin JA; Campbell MJ; Boelaert K; Turnell AS; Smith VE; McCabe CJ
Cancer Res; 2020 Jan; 80(1):102-115. PubMed ID: 31672844
[TBL] [Abstract][Full Text] [Related]
16. [Sodium iodide symporter in physiology and diseases -- the current state of knowledge].
Wolny M; Syrenicz A
Endokrynol Pol; 2007; 58(6):512-21. PubMed ID: 18205108
[TBL] [Abstract][Full Text] [Related]
17. Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line.
Choi HJ; Kim TY; Ruiz-Llorente S; Jeon MJ; Han JM; Kim WG; Shong YK; Kim WB
Nucl Med Biol; 2012 Nov; 39(8):1275-80. PubMed ID: 22995901
[TBL] [Abstract][Full Text] [Related]
18. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
19. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.
Kogai T; Brent GA
Pharmacol Ther; 2012 Sep; 135(3):355-70. PubMed ID: 22750642
[TBL] [Abstract][Full Text] [Related]
20. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
